For research and educational purposes only. Not medical advice.
Bempedoic acid Reference
Educational, not medical advice reference for Bempedoic acid: Metabolic; regulatory status, evidence posture, source review, and schedule notes. Also known a…
Reference summary
Bempedoic acid is a prodrug activated to the active form (ETC-1002-CoA) only in liver tissue; the activating enzyme is absent in skeletal muscle, which is the rationale for the favorable myalgia profile in statin-intolerant patients. CLEAR Outcomes (Nissen 2023 NEJM, n=13,970) randomized statin-intolerant patients to bempedoic acid 180 mg daily vs placebo and reported a 13 percent relative reduction in the primary 4-component MACE composite over a median 3.4 years.
Regulatory and posture
- Categories
- Metabolic
- Aliases
- Nexletol, ETC-1002, ATP-citrate lyase inhibitor (small molecule, not a peptide)
- Evidence posture
- human
- Regulatory status
- FDA-approved as Nexletol (2020) as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering. A fixed-dose combination with ezetimibe (Nexlizet) is also approved.
- Content review status
- label verified